At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 60 enrolled
Drug / intervention
Ruxolitinib cream +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Mechanism of Action of Ruxolitinib Cream for Vitiligo
In Brief
A Phase 2 clinical trial evaluating Ruxolitinib cream and Vehicle Cream for Vitiligo. Completed, enrolled 60 participants across 13 sites in 3 countries.
Detailed Summary
The purpose of the study is to evaluate the Mechanism Of Action (MOA) of ruxolitinib cream in vitiligo by assessing the change in biomarkers.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVitiligo
CountriesCanada, France, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedMay 2021
Enrollment StartJun 2021
Primary CompletionNov 2022
Study CompletionJul 2023
TodayJul 2026
First PostedMay 21, 2021
Enrollment StartJun 23, 2021
Primary CompletionNov 17, 2022
Study CompletionJul 10, 2023
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 5.1 years ago
Interventions
Ruxolitinib creamdrug
Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
Vehicle Creamdrug
Vehicle cream is matching in appearance to ruxolitinib cream and is to be applied in the same manner as ruxolitinib cream.